Relationship between body surface area and ALT normalization after long-term lamivudine treatment

World Journal of Gastroenterology

Volumn 11, Issue 44, 2005, Pages 6948-6953

  Nakamuta, Makoto ^a   Morizono, Shusuke ^a   Tanabe, Yuichi ⁱ   Kajiwara, Eije ^b   Shimono, Junya ^c   Masumoto, Akihide ^d   Maruyama, Toshihiro ^e   Furusyo, Norihiro ^a   Nomura, Hideyuki ^f   Sakai, Hironori ^g   Takahashi, Kazuhiro ^h   Azuma, Koichi ^a   Shimoda, Shinji ^a   Kotoh, Kazuhiro ^a   Enjoji, Munechika ^a   Hayashi, Jun ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^c Saiseikai Yahata Hospital   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

^e KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^f Shin Kokura Hospital   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^h HAMANOMACHI HOSPITAL   (Japan)

ⁱ Fukuoka City Hospital   (Japan)

Author keywords

Body surface area; Dose; Hepatitis B virus; Lamivudine; Long term treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY SURFACE; CHRONIC DISEASE; CONTROLLED STUDY; DNA DETERMINATION; DRUG DOSE REGIMEN; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTION; THROMBOCYTE COUNT; VIROLOGY;

EID: 31144464804     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i44.6948     Document Type: Article

References (13)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129
2. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-2094
3. Qin LX, Tang ZY. Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol 2003; 9: 385-391
4. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661
5. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA, Thomas HC. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113: 1258-1263
6. Honkoop P, de Man RA, Niesters HG, Main J, Nevens F, Thomas HC, Fevery J, Tyrrell DL, Schalm SW. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepat 1998; 5: 307-312
7. Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, Brinkman K, Meenhorst PL, de Man RA. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002; 24: 173-181
8. Nakamuta M, Kotoh K, Tanabe Y, Kajiwara E, Shimono J, Masumoto A, Maruyama T, Furusyo N, Nomura H, Sakai H, Takahashi K, Azuma K, Shimoda S, Enjoji M, Hayashi J. Body surface area is an independent factor contributing to the effects of lamivudine treatment. Hepatol Res 2005; 31: 13-17
9. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36: 41-66
10. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180
11. Kagawa T, Watanabe N, Kanouda H, Takayama I, Shiba T, Kanai T, Kawazoe K, Takashimizu S, Kumaki N, Shimamura K, Matsuzaki S, Mine T. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. World J Gastroenterol 2004; 10: 1686-1687
12. Zaaijer HL, ter Borg F, Cuypers HT, Hermus MC, Lelie PN. Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol 1994; 32: 2088-2091
13. Chun YK, Kim JY, Woo HJ, Oh SM, Kang I, Ha J, Kim SS. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology 2000; 32: 1154-1162